It has been pointed out that only 34% of IEL patients having FBN1 mutations but lacking the systemic features of MFS would remain as IEL sufferers after reclassification under the new criteria and that approximately 60% of FBN1 mutations that had been considered “EL mutations” would not qualify as such [23]. The gene discussed is FBN1; the disease is Marfan syndrome.